Update summarising the conclusions of the international consultation on male lower urinary tract symptoms

Table 4 Conclusions for medical therapies section

Phytotherapies are not recommended due to evidence from meta-analysis or poor RCT data

Alpha antagonists are recommended

Antimuscarinic agents have mostly been trialled in women, but there is evidence to show their efficacy

Men in antimuscarinic trials have a post void residual of < 250 mL

Men with a PSA > 1.5 or prostate volume > 30 mL are more likely to benefit from a 5-α reductase inhibitor

Combination treatments may be suitable for some men

Discontinuation of the 5-α reductase inhibitor is not recommended as the symptoms are likely to return

Phosphodiesterase inhibitors may be used in men with a combination of LUTS and erectile dysfunction

LUTS: Lower urinary tract symptoms; RCTs: Randomized controlled trials.